ZA200508863B - Template-fixed -hairpin peptidomimetics with CXCR4 antagonizing activity - Google Patents
Template-fixed -hairpin peptidomimetics with CXCR4 antagonizing activity Download PDFInfo
- Publication number
- ZA200508863B ZA200508863B ZA200508863A ZA200508863A ZA200508863B ZA 200508863 B ZA200508863 B ZA 200508863B ZA 200508863 A ZA200508863 A ZA 200508863A ZA 200508863 A ZA200508863 A ZA 200508863A ZA 200508863 B ZA200508863 B ZA 200508863B
- Authority
- ZA
- South Africa
- Prior art keywords
- lower alkyl
- chr
- type
- alkenyl
- alkyl
- Prior art date
Links
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 title claims description 17
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 title claims description 17
- 230000003042 antagnostic effect Effects 0.000 title claims description 13
- 239000000816 peptidomimetic Substances 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 6
- 239000011886 peripheral blood Substances 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 5
- 238000002617 apheresis Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 108010061299 CXCR4 Receptors Proteins 0.000 claims description 4
- 102000012000 CXCR4 Receptors Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 806
- 125000003342 alkenyl group Chemical group 0.000 claims 418
- 125000000539 amino acid group Chemical group 0.000 claims 92
- 239000000047 product Substances 0.000 claims 31
- 125000003545 alkoxy group Chemical group 0.000 claims 29
- -1 4- (phenyl)benzyl Chemical group 0.000 claims 26
- 125000003118 aryl group Chemical group 0.000 claims 19
- 230000008878 coupling Effects 0.000 claims 17
- 238000010168 coupling process Methods 0.000 claims 17
- 238000005859 coupling reaction Methods 0.000 claims 17
- 125000000524 functional group Chemical group 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 239000007795 chemical reaction product Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 101800000268 Leader protease Proteins 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 108010077112 prolyl-proline Proteins 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 241000766026 Coregonus nasus Species 0.000 claims 2
- 206010062016 Immunosuppression Diseases 0.000 claims 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- OSASDIVHOSJVII-WDSKDSINSA-N Arg-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N OSASDIVHOSJVII-WDSKDSINSA-N 0.000 claims 1
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 claims 1
- 101100454393 Homo sapiens LCOR gene Proteins 0.000 claims 1
- 101100383295 Human herpesvirus 6B (strain Z29) U71 gene Proteins 0.000 claims 1
- 241000764238 Isis Species 0.000 claims 1
- 102100038260 Ligand-dependent corepressor Human genes 0.000 claims 1
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 claims 1
- 101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 claims 1
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims 1
- 238000006073 displacement reaction Methods 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 6
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001435619 Lile Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- WGGSNNMSSGLKHI-HLICZWCASA-N chembl525205 Polymers C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)=O)CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCNC(N)=N)=O)C(C)C)C1=CC=CC=C1 WGGSNNMSSGLKHI-HLICZWCASA-N 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 108010056903 polyphemusin II Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Detergent Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2003/004640 WO2004096839A1 (en) | 2003-05-02 | 2003-05-02 | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200508863B true ZA200508863B (en) | 2007-03-28 |
Family
ID=33395700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200508863A ZA200508863B (en) | 2003-05-02 | 2005-11-01 | Template-fixed -hairpin peptidomimetics with CXCR4 antagonizing activity |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7786078B2 (ja) |
| EP (3) | EP2540735B1 (ja) |
| JP (3) | JP4846564B2 (ja) |
| KR (5) | KR20130059463A (ja) |
| CN (1) | CN1802385B (ja) |
| AU (2) | AU2003232253A1 (ja) |
| BR (3) | BR122019016211B8 (ja) |
| CA (3) | CA2524253C (ja) |
| EA (1) | EA010163B1 (ja) |
| ES (3) | ES2563094T3 (ja) |
| HK (1) | HK1094210A1 (ja) |
| IL (3) | IL171530A (ja) |
| MX (1) | MXPA05011550A (ja) |
| NO (2) | NO333793B1 (ja) |
| NZ (1) | NZ543806A (ja) |
| WO (2) | WO2004096839A1 (ja) |
| ZA (1) | ZA200508863B (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105111280B (zh) * | 2005-02-17 | 2020-01-24 | 波利弗尔有限公司 | 具有蛋白酶抑制活性的模板固定的β-发夹肽模拟物 |
| KR101272633B1 (ko) | 2005-02-17 | 2013-06-10 | 유니베르시태트 취리히 | 프로테아제 저해 활성을 가지는 주형-고정된 β-헤어핀구조의 펩티드모방체 |
| ATE520705T1 (de) | 2005-05-02 | 2011-09-15 | Polyphor Ltd | Farbstoffkonjugate von schablonenfixierten peptidomimetika |
| JP5251127B2 (ja) | 2005-10-28 | 2013-07-31 | 小野薬品工業株式会社 | 塩基性基を含有する化合物およびその用途 |
| PT1961744E (pt) | 2005-11-18 | 2013-05-15 | Ono Pharmaceutical Co | Composto que contém um grupo básico e sua utilização |
| WO2007079597A1 (en) * | 2006-01-16 | 2007-07-19 | Polyphor Ltd. | Template - fixed peptidomimetics with antimicrobial activity |
| WO2008092281A1 (en) | 2007-01-29 | 2008-08-07 | Polyphor Ltd. | Template-fixed peptidomimetics |
| CN101641372B (zh) * | 2007-02-28 | 2012-11-28 | 波利弗尔有限公司 | 模板固定的肽模拟物 |
| WO2009074807A2 (en) | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
| WO2010015287A2 (en) * | 2008-08-08 | 2010-02-11 | Polyphor Ag | Template-fixed peptidomimetics |
| WO2010060479A1 (en) * | 2008-11-26 | 2010-06-03 | Polyphor Ag | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| WO2010127704A1 (en) * | 2009-05-07 | 2010-11-11 | Polyphor Ag | Beta-hairpin peptidomimetics having cxcr4 antagonizing activity |
| WO2012168336A1 (en) * | 2011-06-07 | 2012-12-13 | Polyphor Ag | Beta - hairpin peptidomimetics as cxc4 antagonists |
| AR087363A1 (es) * | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
| WO2013050346A1 (en) | 2011-10-07 | 2013-04-11 | Polyphor Ag | Template -fixed peptidomimetics as inhibitors of fpr1 |
| CN104603145B (zh) * | 2012-06-06 | 2018-05-18 | 波利弗尔股份公司 | β-发夹肽模拟物 |
| RS56350B1 (sr) * | 2012-08-08 | 2017-12-29 | Polyphor Ag | Kombinacije sa peptidom sa ciklizovanim osnovnim lancem |
| JP6819573B2 (ja) * | 2015-03-24 | 2021-01-27 | 東レ株式会社 | 布帛および衣料 |
| EP3370518B1 (en) | 2015-10-14 | 2023-08-23 | X-Therma, Inc. | Compositions and methods for reducing ice crystal formation |
| US11858974B2 (en) * | 2017-05-22 | 2024-01-02 | Resq Biotech | Macrocyclic modulators of disease associated protein misfolding and aggregation |
| WO2023227771A1 (en) | 2022-05-27 | 2023-11-30 | Fundación Privada Instituto De Salud Global Barcelona | Cyclic peptides with antibacterial activity against multidrug resistant (mdr) pathogens |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2136696C1 (ru) | 1993-10-14 | 1999-09-10 | Сейкагаку Корпорейшн | Новый полипептид и фармацевтическая композиция против вич-инфекции |
| CA2382931C (en) * | 1999-08-30 | 2011-01-25 | Polyphor Ag | Synthesis of template-fixed .beta.-hairpin loop mimetics |
| AU2002247724B2 (en) * | 2001-02-23 | 2008-02-07 | Polyphor Ltd. | Template-fixed peptidomimetics with antimicrobial activity |
| CN101157924A (zh) * | 2001-12-11 | 2008-04-09 | 人体基因组科学有限公司 | 嗜中性白细胞因子α |
| BRPI0215855B1 (pt) * | 2002-08-20 | 2016-12-13 | Polyphor Ltd | peptídeos cíclicos ligados à matriz com ação antimicrobiana |
| ATE393774T1 (de) | 2002-10-02 | 2008-05-15 | Polyphor Ltd | Matrizenfixierte peptidomimetika mit antimikrobieller wirkung |
-
2003
- 2003-05-02 AU AU2003232253A patent/AU2003232253A1/en not_active Abandoned
- 2003-05-02 WO PCT/EP2003/004640 patent/WO2004096839A1/en active Application Filing
-
2004
- 2004-04-29 AU AU2004234062A patent/AU2004234062B2/en not_active Expired
- 2004-04-29 ES ES12185927.6T patent/ES2563094T3/es not_active Expired - Lifetime
- 2004-04-29 EP EP12185905.2A patent/EP2540735B1/en not_active Expired - Lifetime
- 2004-04-29 WO PCT/EP2004/004535 patent/WO2004096840A1/en active Application Filing
- 2004-04-29 KR KR1020137011887A patent/KR20130059463A/ko not_active Application Discontinuation
- 2004-04-29 EP EP12185927.6A patent/EP2540736B1/en not_active Expired - Lifetime
- 2004-04-29 KR KR1020137011885A patent/KR20130059462A/ko not_active Application Discontinuation
- 2004-04-29 MX MXPA05011550A patent/MXPA05011550A/es active IP Right Grant
- 2004-04-29 BR BR122019016211A patent/BR122019016211B8/pt active IP Right Grant
- 2004-04-29 KR KR1020057020836A patent/KR101230453B1/ko active IP Right Grant
- 2004-04-29 CN CN2004800158452A patent/CN1802385B/zh not_active Expired - Lifetime
- 2004-04-29 ES ES12185905.2T patent/ES2550856T3/es not_active Expired - Lifetime
- 2004-04-29 BR BRPI0409928A patent/BRPI0409928B8/pt active IP Right Grant
- 2004-04-29 ES ES04730251.8T patent/ES2550241T3/es not_active Expired - Lifetime
- 2004-04-29 JP JP2006505321A patent/JP4846564B2/ja not_active Expired - Lifetime
- 2004-04-29 BR BR122019016210A patent/BR122019016210B8/pt active IP Right Grant
- 2004-04-29 CA CA2524253A patent/CA2524253C/en not_active Expired - Lifetime
- 2004-04-29 EP EP04730251.8A patent/EP1622931B1/en not_active Expired - Lifetime
- 2004-04-29 KR KR1020117013434A patent/KR101330239B1/ko active IP Right Grant
- 2004-04-29 CA CA2847486A patent/CA2847486C/en not_active Expired - Lifetime
- 2004-04-29 EA EA200501550A patent/EA010163B1/ru not_active IP Right Cessation
- 2004-04-29 KR KR1020117013433A patent/KR101330238B1/ko active IP Right Grant
- 2004-04-29 CA CA2847490A patent/CA2847490C/en not_active Expired - Lifetime
- 2004-04-29 NZ NZ543806A patent/NZ543806A/en not_active IP Right Cessation
- 2004-04-29 US US10/555,088 patent/US7786078B2/en active Active
-
2005
- 2005-10-23 IL IL171530A patent/IL171530A/en active IP Right Grant
- 2005-11-01 ZA ZA200508863A patent/ZA200508863B/en unknown
- 2005-11-25 NO NO20055585A patent/NO333793B1/no unknown
-
2006
- 2006-12-22 HK HK06114147.7A patent/HK1094210A1/xx not_active IP Right Cessation
-
2010
- 2010-07-01 US US12/828,998 patent/US8895695B2/en active Active
-
2011
- 2011-02-18 JP JP2011033325A patent/JP5307169B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-17 JP JP2013104857A patent/JP5770781B2/ja not_active Expired - Lifetime
- 2013-08-08 NO NO20131086A patent/NO340835B1/no not_active IP Right Cessation
- 2013-08-13 IL IL227932A patent/IL227932B/en active IP Right Grant
- 2013-08-13 IL IL227933A patent/IL227933B/en active IP Right Grant
-
2014
- 2014-09-24 US US14/495,737 patent/US9518092B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200508863B (en) | Template-fixed -hairpin peptidomimetics with CXCR4 antagonizing activity | |
| JP6047231B2 (ja) | β−ヘアピンペプチド模倣薬 | |
| CN114736272B (zh) | 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用 | |
| CN109922818B (zh) | Cxcr4拮抗剂及使用方法 | |
| ES2552944T3 (es) | Peptidomiméticos de horquilla beta como antagonistas de CXCR4 | |
| AU2005327825A1 (en) | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity | |
| ES2306924T3 (es) | Peptidomimeticos fijados a una matriz como medicamentos contra el vih y el cancer. | |
| CN115109123B (zh) | 一种抗冠状病毒的多肽、其衍生物及其应用 | |
| WO2010060479A1 (en) | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity | |
| CN108295244B (zh) | 用于治疗乳腺肿瘤的多肽 | |
| CN102731626B (zh) | 环肽及其医药用途 | |
| KR20190046260A (ko) | Ncoa1/stat6 단백질-단백질 상호작용을 저해하는 신규 스테이플 펩타이드 및 이의 용도 | |
| WO2024217209A1 (zh) | 冠状病毒多肽类融合抑制剂的长效化的方法 | |
| CN116440285A (zh) | 冠状病毒多肽类融合抑制剂的长效化的方法 |